Endocrinol Metab.  2015 Dec;30(4):509-513. 10.3803/EnM.2015.30.4.509.

Clinical Characteristics of Subjects with Sulfonylurea-Dependent Type 2 Diabetes

• Min SH
• Kwak SH
• Cho YM
• Park KS
• Jung HS

• KMID: 2169660
• DOI: http://doi.org/10.3803/EnM.2015.30.4.509

Abstract

BACKGROUND
Even though several oral anti-diabetic drugs (OAD) with various modes of action are replacing sulfonylurea (SU), some patients seem to be dependent on SU for adequate glycemic control. Therefore, we evaluated the clinical characteristics of such patients.
METHODS
We selected the patients with type 2 diabetes who met following criteria from 2009 to 2014 at Seoul National University Hospital: glycated hemoglobin (HbA1c) was maintained below 7.5% for at least 6 months under small dose of SU (glimepiride < or =2 mg/day or equivalent dose); after discontinuation of SU, HbA1c increased > or =1.2% within 3 months or > or =1.5% within 6 months; and after resuming SU, HbA1c reduction was > or =0.8% or reduction of fasting plasma glucose was > or =40 mg/dL within 3 months. Patients with impaired hepatic or renal function, and steroid users were excluded.
RESULTS
Nineteen subjects were enrolled: after averaged 4.8+/-1.5 months of SU-free period, HbA1c increased from 6.7%+/-0.4% to 8.8%+/-0.8% even though adding other OAD such as gliptins. However, HbA1c decreased to 7.4%+/-0.7% after resuming SU within 2.4+/-0.8 months. There was no sexual predominance. Despite their old age (67+/-11 years) and long duration of diabetes (18+/-10 years), fasting C-peptide was relatively well-reserved (3.9+/-2.6 ng/mL), and nephropathy was not observed (albumin-creatinine ratio 21.2+/-16.6 mg/g and estimated glomerular filtration rate 75.8+/-18.0 mL/min/1.73 m2). Strong family history was also noted (73.7%).
CONCLUSION
Despite hypoglycemia risk of SU, it seemed indispensable for a subset of patients with regard to insulin secretion. Genetic influences would be evaluated.

Keyword

Sulfonylurea; Diabetes mellitus; Insulin secretion

MeSH Terms

Blood Glucose
C-Peptide
Diabetes Mellitus
Dipeptidyl-Peptidase IV Inhibitors
Fasting
Glomerular Filtration Rate
Hemoglobin A, Glycosylated
Humans
Hypoglycemia
Insulin
Seoul
C-Peptide
Dipeptidyl-Peptidase IV Inhibitors
Insulin

Reference

1. Standards of medical care in diabetes: 2015: summary of revisions. Diabetes Care. 2015; 38:Suppl. S4.

2. Ko SH, Kim SR, Kim DJ, Oh SJ, Lee HJ, Shim KH, et al. 2011 Clinical practice guidelines for type 2 diabetes in Korea. Diabetes Metab J. 2011; 35:431–436.

3. Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545–2559.

4. McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012; 35:1897–1901.

5. Williams SA, Pollack MF, Dibonaventura M. Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2011; 91:363–370.

6. Cryer PE. Banting Lecture. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes. 1994; 43:1378–1389.

7. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011; 32:1900–1908.

8. Wheeler S, Moore K, Forsberg CW, Riley K, Floyd JS, Smith NL, et al. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy. Diabetologia. 2013; 56:1934–1943.

9. Oishi M, Yamazaki K, Okuguchi F, Sugimoto H, Kanatsuka A, Kashiwagi A, et al. Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002-2011 in Japan (JDDM32). J Diabetes Investig. 2014; 5:581–587.

10. University of Kentuchy. Sulfonylurea dosage conversion table [Internet]. Lexington: University of Kentuchy;c2002. updated 2006 Aug 13. cited 2015 Mar 12. Available from: http://www.hosp.uky.edu/pharmacy/formulary/formtools/sulfonylurea.htm.

11. Kimberley Standard Drug List. Switching sulphonylureas [Internet]. Broome: Kimberley Aboriginal Medical Services Council;c2010. cited 2015 Mar 12. Available from: http://www.ksdl.kamsc.org.au/dtp/switching_sulphonylureas.html.

12. Jeong SU, Kang DG, Lee DH, Lee KW, Lim DM, Kim BJ, et al. Clinical characteristics of type 2 diabetes patients according to family history of diabetes. Korean Diabetes J. 2010; 34:222–228.

13. Park JY, Lee KU, Kim CH, Kim HK, Hong SK, Park KS, et al. Past and current obesity in Koreans with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1997; 35:49–56.

14. Koo BK, Kim SW, Yi KH, Park KS, Moon MK. Changing relative contribution of abdominal obesity and a family history of diabetes on prevalence of diabetes mellitus in Korean men and women aged 30-49 years from 2001 to 2010. J Diabetes. 2015; 7:465–472.

15. Chan WB, Tong PC, Chow CC, So WY, Ng MC, Ma RC, et al. The associations of body mass index, C-peptide and metabolic status in Chinese type 2 diabetic patients. Diabet Med. 2004; 21:349–353.

16. Lee WJ, Sobrin L, Lee MJ, Kang MH, Seong M, Cho H. The relationship between diabetic retinopathy and diabetic nephropathy in a population-based study in Korea (KNHANES V-2, 3). Invest Ophthalmol Vis Sci. 2014; 55:6547–6553.

17. Rim TH, Byun IH, Kim HS, Lee SY, Yoon JS. Factors associated with diabetic retinopathy and nephropathy screening in Korea: the Third and Fourth Korea National Health and Nutrition Examination Survey (KNHANES III and IV). J Korean Med Sci. 2013; 28:814–820.

18. Holt RI. Textbook of diabetes. 4th ed. Chichester: Wiley-Blackwell;2010. p. 460–461.

19. Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT, et al. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care. 2008; 31:204–209.